

## **WARNING**

This material has been reproduced and communicated to you by or on behalf of the University of Melbourne in accordance with section 113P of the *Copyright Act 1968* (**Act**).

The material in this communication may be subject to copyright under the Act.

Any further reproduction or communication of this material by you may be the subject of copyright protection under the Act.

**Do not remove this notice**

# Veterinary Bioscience: Cells to Systems

VETS30029 / VETS90121




## Nicotinic Receptors and the Neuromuscular Junction

Graham Mackay

[gmackay@unimelb.edu.au](mailto:gmackay@unimelb.edu.au)

# Cholinergic Nerves




# The Neuromuscular Junction


Transmitter- ACh

Receptor- Nicotinic AChR

Conti-Fine et al, 2006.  
JCI 116;2843




# Nicotinic ACh Receptor



*Rang et al; Pharmacology 6<sup>th</sup> Edition; Churchill Livingstone, 2007*

# The Nicotinic ACh Receptor



*Torpedo marmorata*

# The Nicotinic ACh Receptor



Miyazawa et al, 2003. Nature 423;949.



# The Nicotinic ACh Receptor




*Bungarus multicinctus*

*Taiwanese banded krait*



# $\alpha$ -Bungarotoxin

Binds with high  
affinity and blocks  
NicR




<http://opm.phar.umich.edu/protein.php?pdbid=1hc9>

# $\alpha$ -Bungarotoxin


- A tool for purifying NicR
  - Permitted structural analysis
  - Permitted protein isolation, that led to sequencing and gene cloning
- A tool for visualising/understanding the NMJ and NicR
- A diagnostic tool- *myasthenia gravis*

# $\alpha$ -Bungarotoxin



[www.mcb.harvard.edu/Faculty/Gallery/Lichtman2.jpg](http://www.mcb.harvard.edu/Faculty/Gallery/Lichtman2.jpg)

# Anticholinesterase drugs




# Anticholinesterases

---


- **Drugs in this category have:**
- **Variable selectivity**
  - between NMJ and postganglionic parasympathetic junctions
- **Variable CNS access**
- **Variable duration of action**
  - Short-Acting; Medium-Duration; Irreversible

# What is Myasthenia Gravis?



**A** Complement binding and activation at the NMJ



**B** Antigenic modulation




**C** Functional AChR block








# Treatment of Myasthenia Gravis with Anti-AChE



Normal Contraction of Skeletal Muscle



Reduced Contraction of Skeletal Muscle- Paralysis



Restored Normal Contraction of Skeletal Muscle

# Myasthenia Gravis- “Tensilon” Test

---




***Tensilon = edrophonium  
(short-acting anti-cholinesterase)***

<http://www.youtube.com/watch?v=k7YX9kuWrxA>

# Skeletal muscle relaxant- suxamethonium

- 'Depolarising' muscle relaxant
  - Agonist at NicR (?)
  - (cw mechanism of action of d-tubocurarine)
- Short-lived actions (mostly!)
  - Useful for 'quick' surgical procedures

# Skeletal muscle relaxant- suxamethonium



Modified from: Lockeridge, Pharmac Ther; 1990; 47; 35-60

# Skeletal muscle relaxant- suxamethonium


Suxamethonium  
(active)



Plasma (psuedo/butyryl)  
cholinesterase

inactive

# Skeletal muscle relaxant- suxamethonium



Polymorphic forms of  
plasma cholinesterase

Alters enzyme  
expression/activity

Pharmacogenomics/  
Pharmacogenetics

Modified from: Lockeridge, Pharmac Ther; 1990; 47; 35-60



# Intro to CAL

Using drugs as tools to  
understand  
neurotransmission

# Intro to CAL- 'Virtual Twitch'

- The preparation
- Using the Software
  - Drug additions
  - Washing
  - New Rat
- Measuring responses
- Non-cumulative vs cumulative concentration response
- Play around with it! Try things and see what happens!

